Cancer Research Audrey Hepburn Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by El-Hashemite, N.
Right arrow Articles by Kwiatkowski, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Hashemite, N.
Right arrow Articles by Kwiatkowski, D. J.
[Cancer Research 63, 5173-5177, September 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Loss of Tsc1 or Tsc2 Induces Vascular Endothelial Growth Factor Production through Mammalian Target of Rapamycin1

Nisreen El-Hashemite, Victoria Walker, Hongbing Zhang and David J. Kwiatkowski2

Brigham and Women’s Hospital, Department of Medicine, Hematology Division, Boston, Massachusetts 02115

Mutation in either TSC1 or TSC2 causes the autosomal dominant disorder tuberous sclerosis, in which widespread hamartomas are seen, some of which have a high level of vascularization. Tuberous sclerosis complex (TSC) gene products negatively regulate mammalian target of rapamycin (mTOR) activity. We found that vascular endothelial growth factor (VEGF) is secreted by Tsc1- or Tsc2-null fibroblasts at high levels compared with wild-type cells. In Tsc1+/- mice, serum levels of VEGF were increased and appeared to be associated with the extent of tumor development. Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels. Moreover, short-term treatment of Tsc1+/- mice with rapamycin at 20 mg/kg led to some changes in tumor morphology and a reduction in serum VEGF levels. These observations have three implications. First, TSC gene products regulate VEGF production through a mTOR signaling pathway. Second, serum VEGF levels may be a useful clinical biomarker to monitor the progression of TSC-associated lesions. Last, rapamycin or related inhibitors of mTOR may have therapeutic benefit in TSC both by direct tumor cell killing and by inhibiting the development of TSC lesions through impairment of VEGF production.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. Bhatia, P. A. Northcott, D. Hambardzumyan, B. Govindarajan, D. J. Brat, J. L. Arbiser, E. C. Holland, M. D. Taylor, and A. M. Kenney
Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization
Cancer Res., September 15, 2009; 69(18): 7224 - 7234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis
Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Rosner and M. Hengstschlager
Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1
Hum. Mol. Genet., October 1, 2008; 17(19): 2934 - 2948.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. T. C. Yang, R. Y. L. Yu, A. Agadir, G.-J. Gao, R. Campos-Gonzalez, C. Tournier, and C.-W. Chow
Integration of Protein Kinases mTOR and Extracellular Signal-Regulated Kinase 5 in Regulating Nucleocytoplasmic Localization of NFATc4
Mol. Cell. Biol., May 15, 2008; 28(10): 3489 - 3501.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. C. Land and A. R. Tee
Hypoxia-inducible Factor 1{alpha} Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif
J. Biol. Chem., July 13, 2007; 282(28): 20534 - 20543.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Kaper, N. Dornhoefer, and A. J. Giaccia
Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions
Cancer Res., February 1, 2006; 66(3): 1561 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. Li, F. Takeuchi, J.-a. Wang, C. Fuller, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling
MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development
J. Exp. Med., September 6, 2005; 202(5): 617 - 624.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
W. W. Chen, D. C. Chan, C. Donald, M. B. Lilly, and A. S. Kraft
Pim Family Kinases Enhance Tumor Growth of Prostate Cancer Cells
Mol. Cancer Res., August 1, 2005; 3(8): 443 - 451.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. C. Mak, H. L. Kenerson, L. D. Aicher, E. A. Barnes, and R. S. Yeung
Aberrant {beta}-Catenin Signaling in Tuberous Sclerosis
Am. J. Pathol., July 1, 2005; 167(1): 107 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C.-L. Gau, J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
Mol. Cancer Ther., June 1, 2005; 4(6): 918 - 926.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. El-Hashemite, V. Walker, and D. J. Kwiatkowski
Estrogen Enhances whereas Tamoxifen Retards Development of Tsc Mouse Liver Hemangioma: A Tumor Related to Renal Angiomyolipoma and Pulmonary Lymphangioleiomyomatosis
Cancer Res., March 15, 2005; 65(6): 2474 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
K. Inoki, H. Ouyang, Y. Li, and K.-L. Guan
Signaling by Target of Rapamycin Proteins in Cell Growth Control
Microbiol. Mol. Biol. Rev., March 1, 2005; 69(1): 79 - 100.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Govindarajan, D. J. Brat, M. Csete, W. D. Martin, E. Murad, K. Litani, C. Cohen, F. Cerimele, M. Nunnelley, B. Lefkove, et al.
Transgenic Expression of Dominant Negative Tuberin through a Strong Constitutive Promoter Results in a Tissue-specific Tuberous Sclerosis Phenotype in the Skin and Brain
J. Biol. Chem., February 18, 2005; 280(7): 5870 - 5874.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. B. Heimberger, E. Wang, E. C. McGary, K. R. Hess, V. K. Henry, T. Shono, Z. Cohen, J. Gumin, R. Sawaya, C. A. Conrad, et al.
Mechanisms of action of rapamycin in gliomas
Neuro-oncol, January 1, 2005; 7(1): 1 - 11.
[Abstract] [PDF]

Home page
 Genes Dev.Home page
J. Brugarolas, K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, L. W. Ellisen, and W. G. Kaelin Jr.
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
Genes & Dev., December 1, 2004; 18(23): 2893 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
B. D. Manning
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis
J. Cell Biol., November 8, 2004; 167(3): 399 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
N. Pore, S. Liu, H.-K. Shu, B. Li, D. Haas-Kogan, D. Stokoe, J. Milanini-Mongiat, G. Pages, D. M. O'Rourke, E. Bernhard, et al.
Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism
Mol. Biol. Cell, November 1, 2004; 15(11): 4841 - 4853.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Kaelin Jr.
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6290S - 6295S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Dutcher
Mammalian Target of Rapamycin Inhibition
Clin. Cancer Res., September 15, 2004; 10(18): 6382S - 6387S.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
M. N. Corradetti, K. Inoki, N. Bardeesy, R. A. DePinho, and K.-L. Guan
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome
Genes & Dev., July 1, 2004; 18(13): 1533 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. El-Hashemite, H. Zhang, V. Walker, K. M. Hoffmeister, and D. J. Kwiatkowski
Perturbed IFN-{gamma}-Jak-Signal Transducers and Activators of Transcription Signaling in Tuberous Sclerosis Mouse Models: Synergistic Effects of Rapamycin-IFN-{gamma} Treatment
Cancer Res., May 15, 2004; 64(10): 3436 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Han, T. M. Santos, A. Puga, J. Roy, E. A. Thiele, M. McCollin, A. Stemmer-Rachamimov, and V. Ramesh
Phosphorylation of Tuberin as a Novel Mechanism for Somatic Inactivation of the Tuberous Sclerosis Complex Proteins in Brain Lesions
Cancer Res., February 1, 2004; 64(3): 812 - 816.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.